MicroRNA-561 affects proliferation and cell cycle transition through PTEN/AKT signaling pathway by targeting P-REX2a in NSCLC.
In this study, we discovered that miR-561 expression was downregulated in human NSCLC tissues and cell lines. The overexpression of miR-561 inhibited NSCLC cell proliferation and cell cycle G1-S transition and induced apoptosis. The inhibition of miR-561 facilitated cell proliferation and G1-S transition and suppressed apoptosis. MiR-561 expression was inversely correlated with P-REX2a expression in NSCLC tissues. P-REX2a was confirmed to be a direct target of miR-561 by using a luciferase reporter assay. The overexpression of miR-561 decreased P-REX2a expression, and the suppression of miR-561 increased P-REX2a expression...
Source: Oncology Research - November 13, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Long non-coding RNA KCNQ1OT1 accelerates the progression of ovarian cancer via microRNA-212-3/ LCN2 axis.
Authors: Lu X, Wang F, Fu M, Li Y, Wang L Abstract Long non-coding RNA KCNQ1OT1 (KCNQ1OT1) has been identified to be deregulated in several kinds of cancers. However, its expression pattern and functions in ovarian cancer remains unknown. Bioinformatics analysis showed that miR-212-3p, an identified suppressor in ovarian cancer, was a direct target of KCNQ1OT1, suggesting that KCNQ1OT1 may play a role in ovarian cancer progression via targeting miR-212-3p. Here, we aimed to explore the effect of KCNQ1OT1 on the carcinogenesis of ovarian cancer, as well as to investigate miR-212-3p roles in this process. The express...
Source: Oncology Research - October 29, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Apatinib monotherapy or combination therapy for non-small cell lung cancer patients with brain metastases.
In this study, we aimed to explore the efficacy and safety profile of apatinib monotherapy, or combined with chemotherapy or endothelial growth factor receptor (EGFR)-TKI in heavily pretreated non-small cell lung cancer (NSCLC) patients with brain metastases. We performed a retrospective analysis for relapsed NSCLC patients with brain metastases from our institute, whom received apatinib (250mg or 500mg p.o. qd) monotherapy, or combination with EGFR-TKI or chemotherapy as second- or more line systemic therapy until disease progression or unacceptable toxicity occurred. The objective response rate (ORR), disease control rat...
Source: Oncology Research - October 17, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Cost-utility analysis of pembrolizumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer with different PD-L1 expression levels.
Authors: Weng X, Luo S, Lin S, Zhong L, Li M, Xin R, Huang P, Xu X Abstract To evaluate the cost-utility of pembrolizumab versus chemotherapy as the first-line setting for metastatic non-small cell lung cancer (NSCLC) from the US health care system perspective. A Markov model was developed to compare the life-time cost and effectiveness of pembrolizumab versus chemotherapy for untreated metastatic NSCLC, based on the clinical data derived from phase III randomized controlled trial (KEYNOTE-042, ClinicalTrials.gov, NCT02220894). Weibull distribution was fitted to simulate the parametric survival functions. Drug cost...
Source: Oncology Research - October 17, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Pathway mutations in breast cancer using whole-exome sequencing.
Authors: Chang YS, Chang CM, Lin CY, Chao DS, Huang HY, Chang JG Abstract The genomic landscape of breast cancer (BC) is complex. The purpose of this study was to decipher the mutational profiles of Taiwanese patients with BC using next-generation sequencing. We performed whole-exome sequencing on DNA from 24 tumor tissue specimens from BC patients. Sanger sequencing was used to validate the identified variants. Sanger sequencing was also performed on paired adjacent non-tumor tissues. After genotype calling and algorithmic annotations, we identified 49 deleterious variants in canonical cancer-related genes in our ...
Source: Oncology Research - October 3, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Efficacy and safety of drug-eluting beads transarterial chemoembolization by CalliSpheres ® in 275 hepatocellular carcinoma patients: results from the Chinese CalliSpheres® Transarterial Chemoembolization In Liver Cancer (CTILC) study.
Efficacy and safety of drug-eluting beads transarterial chemoembolization by CalliSpheres® in 275 hepatocellular carcinoma patients: results from the Chinese CalliSpheres® Transarterial Chemoembolization In Liver Cancer (CTILC) study. Oncol Res. 2019 Sep 26;: Authors: Sun J, Zhou G, Xie X, Gu W, Huang J, Zhu D, Hu W, Hou Q, Shi C, Li T, Zhang X, Ji W, Ying S, Peng Z, Zhou J, Yu Z, Ji J, Du H, Guo X, Fang J, Han J, Xu H, Sun Z, Yu W, Shao G, Wu X, Hu H, Li L, Zheng J, Luo J, Chen Y, Cao G, Hu T Abstract The purpose of this study was to investigate the efficacy and safety of drug-eluting beads tr...
Source: Oncology Research - September 29, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Loss of Fingerprints as a Side Effect of Capecitabine Therapy: Case Report and Literature Review.
This report describes a patient who lost her fingerprints during the early stage of chemotherapy. Our aim is to draw the medical profession's attention to this problem. Consent from the patient's family and approval by the ethics committee of our hospital have been obtained. PMID: 31558182 [PubMed - as supplied by publisher] (Source: Oncology Research)
Source: Oncology Research - September 29, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Overexpression of the long non-coding RNA FOXD2-AS1 promotes cisplatin resistance in esophageal squamous cell carcinoma through the miR-195-Akt-mTOR axis.
This study explored the impact of the lncRNA FOXD2-AS1 on cisplatin resistance in ESCC and its possible mechanisms. Upregulation of FOXD2-AS was detected in patients with ESCC and ESCC cells that are resistant to cisplatin. In an in vitro assay, knockdown of FOXD2-AS1 noticeably inhibited cell invasion and growth, triggered cell death, and repressed the stimulation of the Akt/mTOR axis in cisplatin-resistant ESCC cells (TE-1DDP). Conversely, the overexpression of FOXD2-AS1 remarkably increased cell invasion and growth, repressed cell death, and triggered the stimulation of the Akt/mTOR axis in TE-1/DDP cells. These finding...
Source: Oncology Research - September 29, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

MiR-122 inhibits hepatocarcinoma cell progression by targeting LMNB2.
Authors: Li XN, Yang H, Yang T Abstract In the present study, we proposed to investigate the role of miR-122 in hepatocarcinoma progression and to explore the mechanism. In hepatocarcinoma tissues and cells, we used qRT-PCR to validate the miR-122 expression level. Next, we used colony formation by crystal violet staining assay to compare cell proliferation ability, and we used scratch test or transwell assay to compare cell migration or invasion ability. And then we conducted bioinformatics or luciferase reporter gene assay to prove the regulation effect of miR-122 on lamin B2 (LMNB2), and the biological function ...
Source: Oncology Research - September 29, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

PRKAA1 promotes proliferation and inhibits apoptosis of gastric cancer cells through activating JNK1 and Akt pathways.
In conclusion, our findings suggest that PRKAA1 increases proliferation and restrains apoptosis of gastric cancer cells through activating JNK1 and Akt pathways. PMID: 31558185 [PubMed - as supplied by publisher] (Source: Oncology Research)
Source: Oncology Research - September 29, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

The lncRNA FEZF1-AS1 promotes the progression of colorectal cancer through regulating OTX1 and targeting miR-30a-5p.
In this study, we identified an lncRNA, FEZF1 antisense RNA 1 (FEZF1-AS1), and further explored its function and mechanism in CRC. We verified that FEZF1-AS1 is highly expressed in CRC tissues and cell lines. Through functional experiments, we found that reduced levels of FEZF1-AS1 significantly suppressed CRC cell migration, invasion and proliferation and inhibited tumor growth in vivo. Mechanistically, we discovered that reduced levels of the lncRNA FEZF1-AS1 inhibited the activation of epithelial-mesenchymal transition (EMT), the overexpression of OTX1 (Orthodenticle homeobox 1) partially rescued the FEZF1-AS1-induced i...
Source: Oncology Research - July 5, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Profilin 2 Promotes Proliferation and Metastasis of Head and Neck Cancer Cells by Regulating PI3K/AKT/ β-catenin Signaling Pathway.
Profilin 2 Promotes Proliferation and Metastasis of Head and Neck Cancer Cells by Regulating PI3K/AKT/β-catenin Signaling Pathway. Oncol Res. 2019 May 15;: Authors: Zhou K, Chen J, Wu J, Xu Y, Wu Q, Yue J, Song Y, Li S, Zhou P, Tu W, Yang G, Jiang S Abstract Profilin 2 (PFN2) was found to be mainly expressed in neurons and involved in the development of the brain. In recent years, emerging evidence indicated that PFN2 is also significantly up-regulated in various cancers including the head and neck cancer (HNSC) and influences cancer cell proliferation, migration and invasion. However, the role of...
Source: Oncology Research - May 29, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Triptolide inhibits breast cancer cell metastasis through inducing the expression of miR-146a, a negative regulator of Rho GTPase.
Authors: Liu Q, Wang W, Li F, Yu D, Xu C, Hu H Abstract Triptolide, an extract of Tripterygium wilfordii, has been shown to have a potent anti-cancer activity. In the present study, it was found that triptolide could effectively induce apoptosis and inhibit proliferation and invasion in malignant MDA-MB-231 breast cancer cells. The study focused on its effect on inhibiting invasion, which has not been extensively reported to date. We predicted that triptolide may change invasion activity via microRNAs (miRNAs), which have been recognized as important regulators of gene expression. miRNAome variation in MDA-MB-231 c...
Source: Oncology Research - May 12, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Reactive oxygen species mediated Cezanne inactivation by oxidation of its catalytic cysteine residue in hepatocellular carcinoma.
Authors: Yin Z, Yang L, Wu F, Fan J, Xu J, Jin Y, Yang G Abstract Cysteine oxidation occurs at the active site of deubiquitinases (DUBs) during many biologic signaling cascades. Here we report that hepatocellular carcinoma cells (HCC) generated higher levels of endogenous reactive oxygen species (ROS). This elevated ROS production was inhibited by NADPH oxidase inhibitor diphenylene iodonium (DPI) and mitochondria electron chain inhibitor rotenone in HCC cells. Moreover, we found that H₂O₂ could activate NF-κB dependent inflammatory effect through increased induction of matrix metalloproteinase 2 (MMP2), ...
Source: Oncology Research - May 12, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

CRISPR/Cas9-mediated gene knockout of ARID1A promotes primary progesterone resistance by downregulating progesterone receptor B in endometrial cancer cells.
Authors: Wang H, Tang Z, Li T, Liu M, Li Y, Xing B Abstract Medroxyprogesterone (MPA) is used for the conservative treatment of endometrial cancer. Unfortunately, progesterone resistance seriously affects its therapeutic effect. The purpose of the current study was to investigate the influence of deletion of AT-Rich Interactive Domain 1A (ARID1A) in progesterone resistance in Ishikawa cells. Ablation of ARID1A was conducted through the CRISPR/Cas9 technology. Acquired progesterone-resistant Ishikawa (Ishikawa-PR) cells were generated by chronic exposure of Ishikawa cells to MPA. The sensitivity of the parental Ishi...
Source: Oncology Research - May 12, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

MiR-186 suppresses the progression of cholangiocarcinoma cells through inhibition of Twist1.
In conclusion, miR-186 inhibited cell proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) through targeting Twist1 in human CCA. Thus miR-186/Twist1 axis may benefit the development of therapies of CCA. PMID: 31072421 [PubMed - as supplied by publisher] (Source: Oncology Research)
Source: Oncology Research - May 12, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
In conclusion, we found that DEB-TACE achieved higher treatment response and prolonged survival compared with cTACE in Chinese HCC patients. PMID: 31053181 [PubMed - in process] (Source: Oncology Research)
Source: Oncology Research - May 6, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Baicalein Exerts Anticancer Effect in Nasopharyngeal Carcinoma In Vitro and In Vivo.
In conclusion, baicalein could inhibit the growth and proliferation of human nasopharyngeal carcinoma cells, change their cell cycle, and induce apoptosis. Baicalein also effectively limits both CNE1- and CNE2-transplanted tumors in nude mice. Downregulation of Bcl-xl and Mcl-1 proteins and upregulation of Bax and Bad may be involved in the mechanism. PMID: 31053182 [PubMed - in process] (Source: Oncology Research)
Source: Oncology Research - May 6, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

FCY-302, a novel small molecule, induces apoptosis in leukemia and myeloma cells by attenuating key anti-oxidant and mitochondrial enzymes.
Authors: Rajagopalan P, Hakami A, Ragab M, Elbessoumy A Abstract Arylidene analogues are well proven for biological activities. FCY-302, a novel small molecule belonging to this class was screened for its biological efficacy in leukemia and myeloma cells. FCY-302 selectively inhibited proliferation of cancer cells with GI50 values of 395.2 nM, 514.6 nM and 642.4 nM in HL-60, Jurkat and RPMI-8226 cells respectively. The compound also increased Sub G0 peak in the cancer cell cycle and favored apoptosis determined by Annexin V assay. The compound decreased the anti-apoptotic Bcl-2 levels and increased pro apoptotic Ba...
Source: Oncology Research - May 4, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Upregulation of mobility in pancreatic cancer cells by secreted S100A11 through activation of surrounding fibroblasts.
Authors: Mitsui Y, Tomonobu N, Watanabe M, Kinoshita R, Sumardika W, Youyi C, Murata H, Yamamoto KI, Sadahira T, Rodrigo AGH, Takamatsu H, Araki K, Yamauchi A, Yamamura M, Fujiwara H, Inoue Y, Futami J, Saito K, Iioka H, Kondo E, Nishibori M, Toyooka S, Yamamoto Y, Nasu Y, Sakaguchi M Abstract S100A11, a member of S100 family proteins, is actively secreted from pancreatic ductal adenocarcinoma (PDAC) cells. However, the role of the extracellular S100A11 in PDAC progression remains unclear. In the present study, we investigated the extracellular role of S100A11 in cross-talking between PDAC cells and surrounding fib...
Source: Oncology Research - May 4, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

NET1 enhances proliferation and chemoresistance in Acute Lymphoblastic Leukemia cells.
This study therefore not only contributes to a greater understanding of the molecular mechanisms underlying B-ALL progression but also opens the possibility for developing curative interventions. PMID: 31046876 [PubMed - as supplied by publisher] (Source: Oncology Research)
Source: Oncology Research - May 4, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Changes in DNA damage repair gene expression and cell cycle gene expression do not explain radioresistance in tamoxifen-resistant breast cancer.
Authors: Post AEM, Bussink J, Sweep FCGJ, Span PN Abstract Tamoxifen-induced radioresistance, reported in vitro, might pose a problem for patients who receive neo-adjuvant tamoxifen treatment and subsequently receive radiotherapy after surgery. Previous studies suggested that DNA damage repair or cell cycle genes are involved, and could therefore be targeted to preclude the occurrence of cross-resistance. We aimed to characterize the observed cross resistance by investigating gene expression of DNA damage repair genes and cell cycle genes in estrogen receptor-positive MCF-7 breast cancer cells that were cultured to...
Source: Oncology Research - May 4, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

MicroRNA-510 pla ys oncogenic roles in non-small cell lung cancer by directly targeting SRC kinase signaling inhibitor 1.
Authors: Wu W, He L, Huang Y, Hou L, Zhang W, Zhang L, Wu C Abstract Increasing number of studies demonstrated that microRNAs (miRNAs) may play key roles in various cancer carcinogenesis and progression, including non-small cell lung cancer (NSCLC). However, the expressions, roles and mechanisms of miR-510 in NSCLC have, up to now, been largely undefined. In vivo assay showed that miR-510 was upregulated in NSCLC tissues compared with that in adjacent non-tumor lung tissues. MmiR-510 expression was significantly correlated with TNM stage and lymph node metastasis. In vitro assay indicated expressions of miR-510 wer...
Source: Oncology Research - April 16, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

MicroRNA-204 potentiates the sensitivity of acute myeloid leukemia cells to arsenic trioxide.
Authors: Wang Z, Fang Z, Lu R, Zhao H, Gong T, Liu D, Hong L, Ma J, Zhang M Abstract Although arsenic trioxide (ATO) is a well-known anti-leukemic drug used for acute promyelocytic leukemia treatment, the development of ATO resistance is still a big challenge. We previously reported that microRNA-204 (miR-204) was involved in the regulation of acute myeloid leukemia (AML) cell apoptosis, but its role in chemoresistance is poorly understood. In the present study, we showed that miR-204 was significantly increased in AML cells after ATO treatment. Interestingly, the increased miR-204 level was negatively correlated w...
Source: Oncology Research - April 16, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

RAS responsive element binding protein 1 blocks the granulocytic differentiation of myeloid leukemia cells.
Authors: Yao J, Zhong L, Zhong P, Liu D, Yuan Z, Liu J, Yao S, Zhao Y, Chen M, Li L, Liu L, Liu B Abstract RAS responsive element binding protein 1 (RREB1) is a transcription factor which implicated in RAS signaling and multiple tumors. However, the role of RREB1 in acute myeloid leukemia has not been studied. We found that RREB1 is overexpressed in AML patients and myeloid leukemia cell lines (NB4 and HL-60), and RREB1 expression was significantly decreased during granulocytic differentiation of myeloid leukemia cells induced by all-trans retinoic acid (ATRA). Then we performed a RREB1 knockdown assay in NB4 and H...
Source: Oncology Research - April 16, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

The roles of plant-derived Triptolide on non-small cell lung cancer.
Authors: Wei J, Yan Y, Chen X, Qian L, Zeng S, Li Z, Dai S, Gong Z, Xu Z Abstract Over the past decade, natural compounds have been proved to be effective against many human diseases, including cancers. Triptolide (TPL), a diterpenoid triepoxide from the Chinese herb T. wilfordii Hook F, has exhibited attractive cytotoxic activity on several cancer cells. Especially, an increasing number of studies have emphasized the anti-tumor effects of TPL on non-small cell lung cancer (NSCLC). Here, we mainly focused on the key molecular signaling pathways that lead to the inhibitory effects of TPL on human NSCLC, such as mito...
Source: Oncology Research - April 16, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

MiR-148-3p inhibits growth of glioblastoma targeting DNA methyltransferase-1 (DNMT1).
In conclusion, miR-148-3p directly repressed the expression of DNMT1, and inhibited proliferation, migration and invasion by regulating DNMT1-RUNX3 axis and the epithelial-mesenchymal transition in GBM. Our findings provide a new foundation for treatment of patients with GBM. PMID: 30982493 [PubMed - as supplied by publisher] (Source: Oncology Research)
Source: Oncology Research - April 16, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

microRNA-152 inhibits cell proliferation, migration and invasion in breast cancer.
Authors: Maimaitiming A, Wusiman A, Aimudula A, Kuerban X, Su P Abstract The aim of the present study was to investigate the roles of microRNA-152 (miR-152) in the initiation and progression of breast cancer. The expression level of miR-152 was detected in human breast cancer tissue and a panel of human breast cancer cell lines using qRT-PCR. Results found that miR-152 expression was significantly down-regulated in breast cancer tissue samples compared to adjacent noncancerous tissues as well as in breast cancer cell lines. Overexpression of miR-152 significantly suppressed breast cancer cell proliferation, migrati...
Source: Oncology Research - April 16, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

PPAR β/δ Agonist GW501516 Inhibits Tumorigenesis and Promotes Apoptosis of the Undifferentiated Nasopharyngeal Carcinoma C666-1 Cells by regulating miR206.
PPARβ/δ Agonist GW501516 Inhibits Tumorigenesis and Promotes Apoptosis of the Undifferentiated Nasopharyngeal Carcinoma C666-1 Cells by regulating miR206. Oncol Res. 2019 Apr 08;: Authors: Ji Y, Li H, Wang F, Gu L Abstract In previous investigations, we reported that peroxisome proliferator-activated receptor β/δ (PPARβ/δ) activation by GW501516 inhibits proliferation and promotes apoptosis in the undifferentiated C666-1 nasopharyngeal carcinoma (NPC) cells by modulating caspase dependent apoptotic pathway. In the present study, the mechanism by which GW501516 induces a...
Source: Oncology Research - April 16, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

miR-205-5p contributes to paclitaxel resistance and progression of endometrial cancer by downregulating FOXO1.
Authors: Lu Z, Xu Y, Yao Y, Jiang S Abstract Endometrial cancer (EC) is one of the most frequent malignancies occurring in female genital system. miR-205-5p has been reported to involve in the progression of multiple malignancies, including EC. However, the detail function and mechanism of miR-205-5p in chemoresistance of EC have not been defined. qRT-PCR assay was performed to detect miR-205-5p abundance in EC tissues and cell lines. The sensitivity of HEC-1-A and RL95-2 cells to PTX was assessed based on the results of IC50. MTT and flow cytometry (FCM) analyses were carried out to determine cell proliferation an...
Source: Oncology Research - April 16, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

PD-L1 induces epithelial mesenchymal transition in nasopharyngeal carcinoma cells through activation PI3K/AKT pathway.
Authors: Fei Z, Deng Z, Zhou L, Li K, Xia X, Xie R Abstract Nasopharyngeal cancer (NPC) is a malignant epithelial carcinoma of the head and neck. Cancer therapy targeting programmed cell death protein 1 (PD-1) or programmed death ligand-1 (PD-L1) is of revolutionary. However, the tumorigenic mechanism of PD-L1 was not yet clear in NPC. Here we demonstrated an oncogenic role of PD-L1 via activating PI3K/AKT in NPC cells. PD-L1 overexpression was frequently detected in NPC biopsies and cell lines by qRT-PCR. PD-L1 overexpression and knockdown demonstrated that PD-L1 promoted NPC cellsinvasion and metastasis in vitro ...
Source: Oncology Research - April 16, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

High blood miR-802 is associated with poor prognosis in HCC patients by regulating DNA damage response 1 (REDD1)-mediated function of T cells.
In conclusion, miR-802 was involved in T-cell exhaustion through post-transcriptionally suppressing REDD1, which might offer the suppressive effect of miR-802 on HCC progression. PMID: 30982498 [PubMed - as supplied by publisher] (Source: Oncology Research)
Source: Oncology Research - April 16, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Non-steroidal anti-inflammatory drugs sensitize CD44-overexpressing cancer cells to Hsp90 inhibitor through autophagy activation.
In conclusion, combining NSAID with Hsp90 inhibitor may offer one of the most promising strategies for eradication of CD44-overexpressing CSCs. PMID: 30982499 [PubMed - as supplied by publisher] (Source: Oncology Research)
Source: Oncology Research - April 16, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Anticancer effects of Gleditsia sinensis extract in rats transplanted with hepatocellular carcinoma cells.
Authors: Cai Y, Zhang C, Zhan L, Cheng L, Lu D, Wang X, Xu H, Wang S, Wu D, Ruan L Abstract The thorns of Gleditsia sinensis have been historically used in Chinese medicine, and considered one of the fundamental therapeutic herbs. Its anticancer effects are currently being explored. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and still requires the development of new drugs with higher efficiency. By using a rat HCC model implanted with cancerous Walker-256 cells, the therapeutic effects of Gleditsia sinensis extract (GSE) were assessed, as well as its regulatory effects on miRNAs...
Source: Oncology Research - April 5, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Inhibition of proliferation by knockdown of transmembrane (TMEM) 168 in glioblastoma cells via suppression of Wnt/beta-catenin pathway.
Authors: Xu J, Su Z, Ding Q, Shen L, Nie X, Pan X, Yan A, Yan R, Zhou Y, Li L, Lu B Abstract Human glioblastoma multiforme (GBM) accounts for the majority of human brain gliomas. Several TMEM proteins, such as TMEM 45A, TMEM 97, and TMEM 140, are implicated in human brain gliomas. However, the roles of TMEM168 in human GBM remained extremely poor. Herein, we found that mRNA levels of TMEM168 were overexpressed in GBM patients (n = 85) when compared with healthy people (n = 10), which was also supported by data from The Cancer Genome Atlas (TCGA). KaplanMeier analysis of Gene Expression Omnibus dataset GSE16011 sugg...
Source: Oncology Research - April 5, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

E2-induced activation of the NLRP3 inflammasome triggers pyroptosis and inhibits autophagy in HCC cells.
In conclusion, E2-induced activation of the NLRP3 inflammasome may serve as a suppressor in HCC progression, as it triggers pyroptotic cell death and inhibits protective autophagy. PMID: 30940293 [PubMed - as supplied by publisher] (Source: Oncology Research)
Source: Oncology Research - April 5, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

VASH2 promotes cell proliferation and resistance to doxorubicin in non-small cell lung cancer via AKT signaling.
In conclusion, the findings in the present study indicate that VASH2 promotes NSCLC cell proliferation and resistance to doxorubicin via modulation of AKT signaling. Thus, we suggest that VASH2 may become a potential therapeutic target for the treatment of NSCLC. PMID: 30940294 [PubMed - as supplied by publisher] (Source: Oncology Research)
Source: Oncology Research - April 5, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib.
In this study, we retrospectively screened 6,235 advanced NSCLC patients (Stage IIIB to IV) from 5 hospitals and identified 106 patients with ROS1-rearrangements based on either plasma or tumor tissue testing using capture based targeted sequencing. The most frequently occurred fusion partners included cluster of differentiation 74 (CD74), ezrin (EZR), syndecan 4 (SDC4) and tropomyosin 3 (TPM3), occurring in 49.1%, 17%, 14.2% and 4.7% of patients, respectively. Among them, 38 patients were treated with crizotinib. Seventeen patients were treatment-naïve and the remaining were previously treated with pemetrexed-based c...
Source: Oncology Research - April 5, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

The Role of Toll-like Receptors in Oncotherapy.
Authors: Liu C, Han C, Liu J Abstract Toll-like receptors (TLRs) are associated with tumor growth and immunosuppression, as well as apoptosis and immune system activation. TLRs can activate apoptosis and innate and adaptive immunity pathways, which can be pharmacologically targeted for the development of anti-cancer oncotherapies. Several studies and clinical trials indicate that TLR agonists are promising adjuvants or elements of novel therapies, particularly when used in conjunction with chemotherapy or radiotherapy. An increasing number of studies suggests that the activation of TLRs in various cancer types is r...
Source: Oncology Research - April 5, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Extracellular S100A11 plays a critical role in spread of the fibroblast population in pancreatic cancers.
In this study, we hence investigated the significance of the paracrine axis of S100A11-RAGE in fibroblasts for their proliferation activity. In in vitro settings, extracellular S100A11 induced upregulation of fibroblast proliferation. Our mechanistic studies revealed that the induction is through RAGE-MyD88-mTOR-p70 S6 kinase upon S100A11 stimulation. The paracrine effect on fibroblasts is linked mainly to triggering growth but not cellular motility. Thus, the identified pathway might become a potential therapeutic target to suppress PDAC progression through preventing PDAC-associated fibroblast proliferation. PMID: 30...
Source: Oncology Research - March 10, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

PAR2 inhibition enhanced the sensitivity of colorectal cancer cells to 5-FU and reduced EMT signaling.
In this study, we found that protease-activated receptor-2 (PAR2) induction in 5-Fu therapy is correlated with TGF-β-mediated EMT and apoptosis resistance. PAR2 and TGF-β were both activated in response to 5-Fu treatment in vivo and in vitro, and whereas TGF-β inhibition sensitized CRC cells to 5-Fu and suppressed cell migration, PAR2 activation eliminated the effect TGF-β inhibition. Conversely, siRNA-mediated PAR2 depletion or PAR2 inhibition with a specific inhibitor produced a similar phenotype as TGF-β signal inhibition: 5-Fu sensitization and cell-migration suppression. Moreover, the results ...
Source: Oncology Research - March 9, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

MiR-374a inhibitor enhances etoposide-induced cytotoxicity against glioma cells through upregulation of FOXO1.
Authors: Ni W, Luo L, Zuo P, Li R, Xu X, Wen F, Hu D Abstract Glioma is a commonly diagnosed brain tumor that show high mortality rate. Despite the great advancement of cancer therapy in recent years, chemotherapy is still an important approach for treatment of glioma. However, long-term chemotherapy usually causes serious side-effects or complications. We are supposed to take strategies to enhance the efficacy of current chemotherapy. In the present study, we observed obvious upregulation of miR-374a in glioma cells. More importantly, we found that knockdown of miR-374a was able to enhance the etoposide-induced cy...
Source: Oncology Research - March 9, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Synergistic efficacy of the demethylation agent decitabine in combination with the protease inhibitor bortezomib for treating multiple myeloma through the Wnt/ βcatenin pathway.
In this study, we report the effects of single reagent DAC therapy and DAC combined with BZM on β-catenin accumulation, myeloma cell survival, apoptosis and treatment sensitivity. Our study proved that DAC demethylated and induced the re-expression of the Wnt antagonists sFRP3 and DKK1. DAC also reduced GSK3β (Ser9) phosphorylation and decreased β-catenin accumulation in the nucleus, which were induced by BZM. Thus, the transcription of cyclin D1, c-Myc and LEF/TCF was reduced, which synergistically inhibited cell proliferation, enhanced BZM-induced apoptosis, and promoted BZMinduced cell cycle arrest in mye...
Source: Oncology Research - March 7, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

miR-203 inhibits the invasion and EMT of gastric cancer cells by directly targeting Annexin A4.
Authors: Li J, Zhang B, Cui J, Liang Z, Liu K Abstract Many studies have shown that down-regulated miR-203 level is in a variety of cancers including gastric cancer (GC). However, the precise molecule mechanisms of miR-203 in GC have not been well clarified. In current study, we investigated the biological functions and molecular mechanisms of miR-203 in GC cell lines. We found that miR-203 is down-regulated in GC tissues and cell lines. Moreover, the low level of miR-203 was associated with increased expression of Annexin A4 in GC tissues and cell lines. The invasion and EMT of GC cells was suppressed by overexpre...
Source: Oncology Research - March 7, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

MiR-101 represses T-cell acute lymphoblastic leukemia by targeting CXCR7/STAT3 axis.
Authors: Yang XY, Sheng Y Abstract Although miR-101 is involved in the development and progression of T-cell acute lymphoblastic leukemia (T-ALL), the underlying molecular mechanisms remain unclear. In this paper, we reported that miR-101 expression was inversely correlated with CX chemokine receptor 7 (CXCR7) level in T-ALL. Introducing miR-101 inhibited T-ALL cell proliferation and invasion in vitro and suppressed tumor growth and lung metastasis in vivo. CXCR7 was identified as a direct target of miR-101. The inhibitory effects of miR-101 were mimicked and counteracted by CXCR7 depletion and overexpression, resp...
Source: Oncology Research - March 7, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Secreted phosphoprotein-1(SPP1) contributes to second generation EGFR tyrosine kinase inhibitor resistance in non-small cell lung cancer.
In this study, we established afatinib acquired resistant cell lines. Gene array technology was used to screen changes in gene expression between afatinib-resistant lung cancer cells and parental cells. Our results showed that secreted phosphoprotein-1 (SPP1) was significantly increased in afatinib-resistant lung cancer cells. To study the effect of SPP1 on afatinib resistance, siSPP1 was used to knockdown SSP1 in afatinib-resistant lung cancer cells. Then sensitivity to afatinib and invasive ability were studied. We found that knockdown of SPP1 increased sensitivity of lung cancer cells to afatinib and decease the ability...
Source: Oncology Research - March 6, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Silencing of lncRNA AFAP1-AS1 inhibits cell growth and metastasis in clear cell renal cell carcinoma.
Authors: Mu Z, Dong D, Wei N, Sun M, Wang W, Shao Y, Gao J, Yin P, Zhao C Abstract LncRNA AFAP1-AS1, oriented from an antisense direction to the protein-coding gene AFAP1 in the opposite strand, was upregulated in a variety of tumors and associated with poor prognosis, including lung cancer, breast cancer, ovarian cancer, and so on. However, the biological role of AFAP1-AS1 in clear cell renal cell carcinoma (ccRCC) is still unknown. Herein, we observed that AFAP1-AS1 expression was significantly upregulated in ccRCC tissues and that patients with high-level expression of AFAP1-AS1 had a shorter overall survival. K...
Source: Oncology Research - March 6, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

MicroRNA-101 targets CXCL12-mediated Akt and Snail signaling pathways to inhibit cellular proliferation and invasion in papillary thyroid carcinoma.
In this study, we demonstrated that miR-101 expression was significantly decreased in PTC tissues and cell lines. Clinically, low level of miR-101 was positively associated with advanced histological stages and lymph node and distant metastases. The expression of CXCL12 was negatively correlated with miR-101 level in PTC. CXCL12 was validated as a direct target of miR-101 in PTC cells. Functional experiments proved that miR-101 markedly reduced the proliferation, apoptosis escape, migration, and invasion of PTC cells. Moreover, CXCL12 restoration rescued the suppressive effects of miR-101 on PTC cells by activating Akt and...
Source: Oncology Research - March 6, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Knockdown of LncRNA PVT1 inhibits glioma progression by regulating miR-424 expression.
This study investigated the function and mechanism of PVT1 knockdown in the proliferation and malignant transformation of human gliomas. We firstly examined the expression levels of PVT1 and miR-424 in human glioma tissues and cell lines. We also used gene manipulation techniques to explore the effects of PVT1 knockdown on cell viability, migration, invasion, and miR-424. We found that PVT1 knockdown effectively inhibited cell viability, migration and invasion of human glioma cells and increased miR-424 expression. Based on the negative correlation between PVT1 and miR-424, we then confirmed the direct interaction between ...
Source: Oncology Research - March 6, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Nutlin-3-induced Sensitization of Non-Small Cell Lung Cancer Stem Cells to Axitinib-Induced Apoptosis through Repression of Akt1/Wnt Signaling.
Authors: Wang M, Wang X, Li Y, Xiao Q, Cui XH, Xiao GD, Wang JC, Xu CW, Ren H, Liu D Abstract To investigate the potential biological activities of nutlin-3 (N-3) in the regulation of growth and proliferation of non-small cell lung cancer (NSCLC)stem cells (CSCs), which may help in sensitizing to axitinib-induced apoptosis. N-3 induction of p53 expression was used to test its role in controlling the cell division pattern and apoptosis of NSCLC cells. A549 cells and H460 cells were pretreated with N-3 and then treated with either an Akt1 activator or shRNA-GSK3β, to investigate the potential role of p53 sensiti...
Source: Oncology Research - March 6, 2019 Category: Cancer & Oncology Tags: Oncol Res Source Type: research